Premier Perspectives The blog for insider insights in clinical development Consulting Ashanthi DeSilva’s Story: A Look Back at the First Gene Therapy Trial By Juliet Moritz November 14, 2018 Featured Posts Medical and Regulatory Affairs Learning to Listen: Voice of the Patient Grows Louder in Product Development By Juliet Moritz March 13, 2018 Clinical ResearchPhase 1 - Phase 4 Choices, Choices: Which Type of Natural History Study Meets Your Needs? By Juliet Moritz August 22, 2017 Recent Posts By expertise area All expertise areas Medical DeviceRare DiseaseOncology & HematologyDiagnosticsDigital TherapeuticsMedTechPediatricsNeuroscienceAnalgesiaDermatologyOtherCOVID-19Cell & Gene TherapyWomen's HealthReal-World & Late PhaseCareers By functional area All functional areas Clinical Research: Phase 1 - Phase 4ConsultingData Management & BiostatisticsFunctional Service Provider (FSP)Global ComplianceMedical and Regulatory AffairsPatient and Stakeholder EngagementProject ManagementQualityReal-World Science and Late PhaseSafety/PharmacovigilanceStudy DesignStudy Start-UpOtherCOVID-19Product Development Consulting 4 Historical Orphan Drug Development Barriers, Have We Broken Through? By Juliet Moritz June 8, 2017 Clinical ResearchPhase 1 - Phase 4 Natural History Studies: A Growing Force in Treating Rare Diseases By Juliet Moritz April 19, 2017 Clinical ResearchPhase 1 - Phase 4 Natural History vs. Registry Studies in Rare Disease By Juliet Moritz April 12, 2017 Consulting The Rise of Patient Advocacy By Juliet Moritz March 28, 2017 Patient and Stakeholder Engagement The Future of Patient Advocacy and Orphan Drug Development: Challenges and Opportunities By Juliet Moritz February 28, 2017 Consulting NORD Summit, a Rare Disease Regulatory Wonderland By Juliet Moritz October 26, 2016 1 2 Next × ALSO OF INTERESTPremier Voices #2: Registry Studies & Natural...
